Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: complement factor 5a inhibitors - Jerini

Drug Profile

Research programme: complement factor 5a inhibitors - Jerini

Alternative Names: JPE-1375; JSM-1375; JSM-7717

Latest Information Update: 24 Mar 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jerini
  • Developer Jerini; Jerini Ophthalmic
  • Class Small molecules
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Age-related macular degeneration; Inflammation

Most Recent Events

  • 10 Apr 2008 Jerini Ophthalmic signs an exclusive licensing and development agreement with PR Pharmaceuticals to develop sustained-release formulations for a variety of ophthalmic indications, including JPE 1375 for age-related macular degeneration
  • 09 Nov 2007 JSM 7717 and JPE 1375 are available for partnering for renal therapy (http://www.jerini.com)
  • 09 Nov 2007 JPE 1375 is available for licensing (http://www.jophth.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top